SCHEMBL10242917

SCHEMBL10242917

CCCNC(=O)Cc1cncc(-c2ccco2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
NPC1 O15118 3/20 0.49
HPGD P15428 3/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
GAA P10253 1/20 0.49
PTPN7 P35236 1/20 0.43
ADORA3 P0DMS8 4/20 0.40
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
KDM4E B2RXH2 4/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
PKM P14618 1/20 0.39
HTT P42858 1/20 0.39
POLB P06746 3/20 0.39
ADORA2A P29274 3/20 0.39
ADORA2B P29275 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10242915 0.84 PRMT6 (0.53) ALDH1A1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL10242926 0.82 ALDH1A1 (0.49) ALDH1A1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL10242902 0.77 PRMT6 (0.51) ALDH1A1HPGDGAAPTPN7KDM4E
SCHEMBL16330614 0.76 PRMT6 (0.46) ALDH1A1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL12303899 0.75 PRMT6 (0.51) ALDH1A1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL10243085 0.74 ALDH1A1 (0.59) ALDH1A1NPC1HPGDRAB9ASMN1; SMN2
SCHEMBL10242931 0.74 PRMT6 (0.56) ALDH1A1HPGDSMN1; SMN2ADORA3CTSS
SCHEMBL4135657 0.73 PRMT6 (0.43) ALDH1A1NPC1HPGDRAB9ALMNA
SCHEMBL10242925 0.72 EPHX2 (0.53) LMNAGAACTSSHTTEPHX2
SCHEMBL10242886 0.71 ALDH1A1 (0.48) ALDH1A1NPC1HPGDRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 ALDH1A1 1939/4885NPC1 209/4885HPGD 556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.